分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

SARS-CoV-2 rORF3, a novel microprotein, impairs interferon-β production by targeting RanBP2 to inhibit p65 nuclear import

Yucong Huang, Jing Jiang, Qingting Xiao, Yajie Wang, Gulinaziya Abulaike, Ayinuer Maimaiti, Pan Gong, Xiaohuang Lin, Fangfang Li, Xueping Zhou, Alexander F. Palazzo, Qingtang Shen

Journal:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF:8.5

DOI:10.1016/j.ijbiomac.2026.150557

PMID:

Published:2026-01-27

research field:生物材料传染病免疫学微生物学材料科学

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19). SARS-CoV-2 encodes various proteins to evade host innate immunity. rORF3 is a novel microprotein encoded by the negative-strand RNA (-RNA) of SARS-CoV-2 that antagonizes type I interferon (IFN-I) production. However, the molecular mechanism by which SARS-CoV-2 rORF3 suppresses IFN-I production remains elusive. Here we report rORF3 interacts with a nucleoporin Ran-Binding Protein 2 (RanBP2), and suppresses IFN-β production and promotes viral infection in a RanBP2-dependent manner. Specifically, we found RanBP2 inhibits the RIG-I-like receptor (RLR)-mediated signaling by targeting p65 and suppressing the nuclear translocation of p65. rORF3 targets RanBP2 and impedes the nuclear translocation of p65 upon tumor necrosis factor-alpha (TNF-α) stimulation, thereby antagonizing IFN-β production. Our findings not only reveal a novel function of RanBP2 in regulating RLR signaling but also provide insights into a new mechanism of the innate immune evasion by SARS-CoV-2.

本文使用的Yeasen产品

购物车
客服
转染试用